Rabeprazole Sodium
It belongs to the class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by the specific inhibition of the H+/K+-ATPase enzyme at the secretory surface of the gastric parietal cell and hence are called proton pump blockers.Rabeprazole is indicated for the treatment of active duodenal ulcer. Active benign gastric ulcer. Symptomatic erosive or ulcerative gastro-oesophageal reflux disease (GORD). H.Pylori-positive duodenal ulcers, as part of the eradication programme with appropriate antibiotics, maintenance treatment of healed erosive or ulcerative GORD. Efficacy has not been demonstrated for periods exceeding 12 months.
Adults/elderly: Active duodenal ulcer and active benign gastric ulcer: 20mg to be taken once daily in the morning. Some patients with active duodenal ulcer may respond to one 10mg tablet to be taken once daily in the morning. Erosive or ucerative gastro-oesophageal reflux disease (GORD):20mg to be taken once daily for four to eight weeks. Gastro-oesophageal reflux disease long-term management (GROD Maintenance): For longterm management up to 12 months, a maintenance dose of rabeprazole 10mg
Hypersensitivity, Pregnancy and lactation.
Gastric or oesophageal malignancy should be excluded prior to commencing treatment with rabeprazole.
Headache, diarrhoea and nausea, rhinitis, abdominal pain, asthenia, flatulence, pharyngitis, vomiting, non-specific pain/back pain,, dizziness, flu syndrome, infection, cough, constipation and insomnia.
Co-administration of rebeprazole sodium results in a 33% decrease in ketoconazole levels and a 22% increase in trough digoxin levels in normal subjects.
